The Motley Fool··James BrumleyPfizer's Monthly GLP-1 Shot Could Crack Novo and Lilly's Weight-Loss Monopoly
Pfizer's experimental monthly GLP-1 injection threatens to disrupt the weight-loss market dominated by Novo Nordisk and Eli Lilly, potentially triggering price competition.
PFELLYNVOGLP-1 drugspharmaceutical competition